Virbac shares rise on strong Q1 revenue growth

Shares in Virbac VIRB.PA jump 3% after the company reported a strong revenue growth in Q1 driven by strategic "supercharge" platforms, and maintained 2026 guidance

The French animal health company published Q1 revenue at 384 million euros ($452.31 million), up 7.7% yoy at constant exchange rate and scope

"Growth is largely driven by the strategic “Supercharge” platforms, which group together the highest value-added franchises of the group (therapeutic nutrition, reproduction, dental, mobility, otology, endocrinology — strengthened by Thyronorm — and ruminants), says TP ICAP Midcap

The broker adds these platforms are growing by around +15% at constant FX and constitute the main structural engine of the organic growth and value-creation trajectory for the group

Jefferies also flags North America leads regional growth at 20.7%, boosted by momentum in mobility, dental and ear product categories as well as a strong ramp-up of the Thyronorm acquisition

It notes that foreign exchange remains a material headwind, weighing approximately 5.5% on reported growth in the quarter

Management reiterates its full-year 2026 guidance, saying the strong first-quarter performance "continued to give confidence" in its annual targets

Including today's gains, the stock is up 4.2% year-to-date

($1 = 0.8490 euros)